The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
The Korean biotech company published the multicenter Phase 1 results in Nature, with 24-week follow-up MRI data that look promising as they continue development.
The companies are working to bring jellyfish-derived Collagen Type Zero to North America, aiming to advance wound care and regenerative medicine with a sustainable alternative to mammalian collagen.
As MEDIPOST ventures abroad, Charles River will provide GMP-compliant biologics and cell therapy testing services to help advance the pipeline into new markets.
The Phase 1 cord blood-derived stem cell therapy for sacroiliac joint-related lower back pain showed an encouraging early safety profile and symptom improvement, supporting plans to begin Phase 2 later this year.
The trial demonstrated that Cartistem can both relieve symptoms and regenerate cartilage, and the company is advancing manufacturing readiness for its first overseas commercialization move.
Researchers in Colorado are advancing injectable and biomaterial-based therapies that, in animal studies, restored damaged cartilage and bone by triggering the body’s own repair processes, potentially offering a minimally invasive alternative to...
Mesoblast said its 300-patient placebo-controlled Phase 3 study of rexlemestrocel-L for chronic low back pain remains on track, with top-line data expected in mid-2027 to support a planned FDA filing for the...
This marks Taiwan’s first GMP facility with mRNA and nucleic acid manufacturing capabilities to expand its CRDMO services and support advanced therapies from development through commercial production.
